Prediction: Here's What a $5,000 Investment in Eli Lilly Could Look Like in 5 Years
Key Points
The company's GLP-1 therapies are adding indications.
Lilly's growing revenue has allowed it to invest heavily in its pipeline.
The company has several promising oncology therapies.
- 10 stocks we like better than Eli Lilly ›
Over the past five years, Eli Lilly (NYSE: LLY) stock managed a total return of 376%. If the stock managed a repeat over the next five years, share prices would top $5,500. Much of its current performance boost is thanks to enthusiasm over its GLP-1 offerings.
Are the same factors that led to the healthcare company's sharp rise likely to recur? The simple answer is no. While its metabolic GLP-1 weight-loss therapies helped spike revenue, it's not likely to happen again. Still, there are reasons to believe the pharmaceutical stock could double in value over the next five years, making a $5,000 investment in Eli Lilly stock worth more than $10,000 in five years. Here's why.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Image source: Getty Images.
The GLP-1 run isn't over
Eli Lilly, through tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, is still a leader in the GLP-1 space. Tirzepatide is showing to be an incredibly versatile incretin-based peptide drug.
Excess weight is tied to many health problems, and tirzepatide could expand to adjacent indications. It has already been approved to treat obstructive sleep apnea, and on Aug. 28, the Food and Drug Administration (FDA) approved Mounjaro to lower the risk of major adverse cardiovascular (CV) events, including cardiovascular death, non-fatal heart attack, or non-fatal stroke in adults with type 2 diabetes who are at high risk.
Other indications that could soon follow include heart failure with preserved ejection fraction (HFpEF) and metabolic dysfunction-associated steatotic liver disease (MASH/NASH).
The pipeline goes beyond metabolic health
In Q2, Mounjaro and Zepbound helped Lilly earn $23 billion in revenue, up 48% year over year. That growth enables the company to invest in a diversified pipeline across oncology, neuroscience, and immunology. Lilly spent $3.8 billion on R&D in the quarter.
It has several promising recent approvals, including Ebglyss for treatment of atopic dermatitis, Kisunla for treatment of early-stage Alzheimer's disease, and Omvoh for the treatment of ulcerative colitis. Those drugs, plus several late-stage cancer therapies, should provide high-margin revenue streams going forward.
Should you buy stock in Eli Lilly right now?
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $421,997!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,413,876!*
Now, it’s worth noting Stock Advisor’s total average return is 978% — a market-crushing outperformance compared to 213% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of September 5, 2026.
James Halley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly. The Motley Fool has a disclosure policy.
Recommended Articles
